LeMaitre Vascular, Inc.

NASDAQ:LMAT

Medical - Instruments & Supplies

Healthcare
$75.58 +1.74%

+$1.60 today

Market cap
$1.73B
Beta
0.52
P/E (TTM)
34.3
EPS (TTM)
$2.74
Dividend yield
0.96%
52W Low $79.01High $118.01

Volume 0.22M

Average 0.26M

LMAT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

LeMaitre Vascular, Inc.NASDAQ: LMAT

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA grows in line with its trailing trend

Q1 FY2026 EBITDA of $23.6M rose 30.5% year over year, behind the +31.7% change in trailing-twelve-month EBITDA. Sequentially, it fell 2.5% from the prior quarter. Over 3 fiscal years it compounded at +35.0% a year.

Context

  • EBITDA amounted to 36.4% of revenue in FY2025, up 6.0 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of $96.37M (+6.1%) for the fiscal year ending Dec 2026, a slowdown from the +36.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.6M-2.5% QoQ
Last fiscal yearDec 2025
$90.79M+36.0% YoY
LTMMar 2026
$96.3M+31.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.5%+28.1%-2.4 pp
1 year+36.0%+6.1%-29.9 pp
3-year CAGR+35.0%+8.8%-26.1 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
90.79M USD
Year-over-year change
+36.0%
4-year CAGR
+18.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How LMAT compares with its peers on the latest reported figures

  • LMAT's LTM Mar 2026 EBITDA of $96.3M is the 5th highest of the 8 companies compared; the peer median is $222.27M.
  • Its year-over-year change of +31.7% is the 2nd highest of 8, against a peer median of +9.8%.
  • EBITDA amounts to 37.6% of revenue for LMAT, versus a peer median of 14.8%.
LMAT Competitors Peer median
EBITDA for LMAT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$10.27B +9.8%+4.1%27.3%
BSXBoston Scientific CorporationLTM Jun 2026$5.8B +23.2%+23.0%27.6%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$341.34M +9.0%+22.4%21.2%
PENPenumbra, Inc.LTM Jun 2026$222.27M +14.8%+95.5%14.8%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$96.3M +31.7%+35.0%37.6%
AORTArtivion, Inc.LTM Mar 2026$65.05M +84.5%+35.4%14.2%
ANGOAngioDynamics, Inc.LTM Feb 2026-$5.44M -1089.6%-46.2%1.7%
TFXTeleflex IncorporatedLTM Jun 2026-$158.49M -126.4%-25.5%6.1%
Peer median (excluding LMAT) $222.27M+9.8%+22.4%14.8%

Competitors are the stored peer set for LMAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue154.42M161.65M193.48M219.86M249.6M
Cost of Revenue53.04M56.76M66.44M68.96M71.06M
Gross Profit101.38M104.9M127.05M150.9M178.54M
Gross Margin65.7%64.9%65.7%68.6%71.5%
Research & Development11.8M13.29M16.97M15.65M14.14M
Selling, General & Admin53.16M61.67M72.89M83M96.49M
Operating Expenses64.96M78.07M90.34M98.65M110.63M
Depreciation & Amortization9.48M9.43M9.52M9.67M10.42M
EBITDA45.98M36.92M48.99M66.75M90.79M
EBITDA Margin29.8%22.8%25.3%30.4%36.4%
Operating Income36.43M26.83M36.71M52.26M67.91M
Operating Margin23.6%16.6%19.0%23.8%27.2%
Interest Income197K986K3.08M4.95M13.09M
Interest Expense2.22M00205K5.18M
Other Income / Expenses(2.14M)661K2.76M4.62M7.27M
Income Before Tax34.29M27.49M39.48M56.88M75.18M
Pre-Tax Margin22.2%17.0%20.4%25.9%30.1%
Income Tax Expense7.38M6.85M9.37M12.84M17.45M
Net Income26.91M20.64M30.11M44.04M57.73M
Net Margin17.4%12.8%15.6%20.0%23.1%
EPS (Basic)1.270.941.361.962.55
EPS (Diluted)1.250.931.341.932.52
Weighted Avg Shares21.16M21.98M22.22M22.45M22.64M
Weighted Avg Shares (Diluted)21.48M22.17M22.42M22.78M22.93M

LeMaitre Vascular, Inc.

NASDAQ:LMAT

Intrinsic Alpha fair value

Locked

Current Price

$75.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.